Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Please read

I agree a huge advantage for us with the exparte review. TPL wants to be thorough and put the prior art issue to bed now and come out of the PTO re-exam with bullet proof patents. TPL is probably focusing their efforts on the PTO re-exam. I'm not sure there is a sence of urgency so much as getting it right. Once re-validated the T3 will settle soon after and the licensing will accelerate IMO. With the SP at these levels a huge opportunity to buy. I just wish I was just coming into this stock.

I have written off the J3's settlement after PTSC answered the contingency question. If something pops up later it's a bonus at this point.

All the best,

Steve



Share
New Message
Please login to post a reply